Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study have shown encouraging signals in acute MS lesions, suggesting that the novel imaging technique may be capable of distinguishing between demyelinated nerve fibers that could still be viable and those that have undergone permanent damage. This distinction is crucial for accurately measuring myelin loss and repair, which are central to the progression and treatment of MS.
The findings are directly relevant to Lucid-MS, the company's investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. A more precise imaging tool and a drug candidate aimed at addressing the underlying cause of MS could form a compelling combination. Reaching the enrollment midpoint with promising early data indicates that the science is holding up under real clinical conditions, according to a recent article on the study.
The pilot study's progress is a significant step for Quantum BioPharma as it advances its pipeline of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company's wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS, a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models of MS.
Beyond its MS program, Quantum BioPharma has also developed unbuzzd, a product aimed at reducing alcohol cravings, and has spun out its over-the-counter version to Unbuzzd Wellness Inc. (UWI). The company retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains full rights to develop similar products for pharmaceutical and medical uses.
The promising preliminary results from the imaging study come at a critical time for the company as it seeks to demonstrate the potential of its lead compound in a clinical setting. The ability to accurately measure myelin repair could accelerate the development of Lucid-MS and provide a valuable biomarker for future clinical trials.
Investors and stakeholders are closely watching the progress of the study, as positive results could significantly impact the company's valuation and the future of MS treatment. The latest news and updates on Quantum BioPharma are available in the company's newsroom at https://nnw.fm/QNTM.
